The purpose of this study was to identify risk factors for hypothyroidism after bone marrow transplantation (BMT) for high-risk or relapsed acute lymphoblastic leukaemia (ALL) in children. In all, 388 children with acute lymphoblastic leukaemia underwent allogeneic bone marrow transplantation between 1984 and 1994. Overall 5-year survival was 54.6%. Thyroid function was assessed in the 153 patients with more than 5 years of follow-up. In total, 16 patients developed uncompensated hypothyroidism (UH) and 46 compensated hypothyroidism (CH) a median of 2.9 and 2.7 years, respectively, after BMT. Thyroid dysfunction-free survival rates were 73.2% after 5 years and 59.2% after 10 years. Three factors were significantly associated with the onset of hypothyroidism, namely age, bone marrow transplantation in second remission, and single-dose total body irradiation (TBI). Ultrasonography of the thyroid showed nodules in 10 of 35 patients. The median time from BMT to nodule detection was 7.8 years. Cytology (n ¼ 5) and surgery (n ¼ 4) showed no evidence of thyroid cancer. Four of the 14 patients who received cytoreduction without TBI but with busulphan and cyclophosphamide developed UH (n ¼ 2) or CH (n ¼ 2). We concluded that children who undergo BMT for ALL are at a high risk of subsequent thyroid dysfunction. Bone Marrow Transplantation (2005) 35, 991-995.
Bone marrow transplantation (BMT) can cure children with acute lymphoblastic leukaemia (ALL) in first complete remission (CR1) or second complete remission (CR2). Data on the long-term outcome of these patients are scant. Cardiac and endocrine disorders are the most frequent late complications, but their precise frequency and determinants are not known. We determined the rate of late thyroid dysfunction in a cohort of 153 children with ALL who underwent allogeneic BMT between 1984 and 1994 and who had a median follow-up of 8.5 years. We also sought risk factors for thyroid dysfunction.
Patients and methods
All patients registered in the database of the French Society for Bone Marrow Transplantation and who underwent allogeneic BMT for ALL between 1984 and 1994 were eligible for the study. Thyroid abnormalities prior to BMT (ectopy, athyreosis, thyroiditis, or Graves disease) were predefined exclusion criteria, but none of the patients had such disorders. TRH stimulation tests were not carried out before BMT, and subclinical primary hypothyroidism cannot therefore be ruled out. The 388 eligible patients were treated in 27 paediatric BMT centres. In 2001-2002, we reviewed the medical records of each patient, on site, focusing on thyroid function. Information on the BMT conditioning regimen and the donor match was also recorded.
No recommendations on thyroid evaluation were made for this study, and each centre monitored the patients according to their institutional protocol. Thyroid function was assessed by palpation, assay of free T4 and TSH, and TRH stimulation studies. Thyroid nodules were measured by ultrasonography. Thyroid cancer was diagnosed histologically. Uncompensated hypothyroidism (UH) was defined as a free T4 level below 10 pmol/l, and compensated peripheral hypothyroidism as a free T4 level above 10 pmol/l with a TSH level above 4 mIU/l or a TRH response greater than 27 mIU/l. For this study, hypothyroidism was defined as uncompensated or compensated peripheral hypothyroidism, whichever occurred first.
In all, 184 patients were alive 5 years after single BMT, and thyroid hormone status was studied in 153 of these patients (83.5%).
Statistical analysis
Stata version 7 software was used for all statistical analyses. Categorical data were compared using Fisher's exact test and quantitative data using the F test. All tests were twotailed. P-values below 0.05 were considered significant. For survival analyses, the period taken into account was the interval between first BMT and the occurrence of an event or last news when no event occurred. Two events were studied, namely death for the survival analysis and hypothyroidism for the late toxicity analysis. The median follow-up was estimated according to the Kaplan-Meier method, last follow-up being the end point for survivors and other patients being censored at death. 1 Survival was compared between groups of subjects by using the log-rank test.
2 The Cox semiparametric model was used for multivariate analysis.
Results
The median follow-up was 8.5 years (range 5-16.6 years) for the 153 patients. The median age at BMT was 8.1 years (range 0.4-15.9 years), and 62% of the patients were males. In all, 26 patients received cranial irradiation before BMT (median 18 Gy), while 140 patients received total body irradiation (TBI) as part of the conditioning regimen (32 single-dose procedures (median 10 Gy) and 108 fractionated TBI (median 1 Gy Â 6)).
Thyroid function studies
A total of 153 patients were evaluated for thyroid function including TRH stimulation in 32 cases. The indications for TRH testing were elevated TSH in 11 patients, nodules in three patients, and routine testing in 18 patients. Eight patients were diagnosed with thyroid dysfunction as a result of TRH testing alone. The demographic and therapeutic characteristics of the 31 patients who did not undergo thyroid evaluation were not different from those of the other patients.
In total, 16 patients had UH and 46 patients had compensated hypothyroidism (CH) (see Table 1 ). None of the patients had clinical signs of hypothyroidism. The median time from BMT to the diagnosis of thyroid dysfunction was 2.9 years (range 1-10.3 years) and 2.7 years (range 0.8-11 years) for UH and CH, respectively (see Table 2 ). Thyroid dysfunction-free survival rates were 73.2% (s.e. 3.6%) after 5 years and 59.2% (s.e. 4.2%) after 10 years ( Figure 1 ).
All the patients with UH and 42 of the 46 patients with CH were receiving thyroid hormone replacement therapy (THRT) at the time of the study.
No episodes of hyperthyroidism, including transient episodes, were recorded. The main reasons for thyroid ultrasonography were routine examination in some centres, and abnormal thyroid hormone assay results. Thyroid ultrasonography was performed in 35 patients, comprising 21 patients with normal thyroid hormone levels, three with UH, and 11 with CH. Of these 35 patients, 10 were found to have nodules (six patients with normal thyroid function, two patients with UH, and two patients with CH). The median time from BMT to nodule detection was 7.8 years (range 1.2-10.3 years), but ultrasound was not performed periodically and the nodules may have appeared earlier. Cytology (n ¼ 5) and surgery (n ¼ 4) showed no evidence of thyroid cancer. None of the six patients with normal thyroid function had taken thyroid hormones before surgery, but three required THRT after surgical removal of their nodules. In one of the two patients with UH, the nodules were found 2.7 years after THRT initiation, whereas in the other patient, the nodules were found 1.2 years before the diagnosis of thyroid dysfunction. Finally, in both patients with CH, the nodules were found 2.7 years after and 6 days before THRT initiation, respectively (see Table 3 ).
Four of the 14 patients who received cytoreduction with busulphan and cyclophosphamide rather than TBI developed UH (n ¼ 2) or CH (n ¼ 2).
Risk factors for hypothyroidism
We first performed univariate analysis of age and gender, the number of remissions (CR 1 or 2) at the time of BMT, cranial irradiation before BMT, the conditioning regimen (particularly the use of cyclophosphamide, busulphan, and TBI, including the modality: single dose vs fractionated), donor match (mismatched unrelated donor, haploidentical, or genoidentical), and age at BMT. Three of these factors were significantly associated with hypothyroidism, namely younger age at BMT, BMT in CR2 (vs CR1), and single-dose TBI as part of the conditioning regimen. In multivariate analysis, these three factors contributed independently to the risk of hypothyroidism, and the most Thyroid toxicity in patients survivors of ABMT for ALL C Berger et al significant predictor of thyroid dysfunction was single-dose TBI (see Table 2 ).
Discussion
This is the largest multicentre nationwide study of longterm thyroid outcome after BMT performed in childhood for acute lymphoblastic leukaemia.
Late thyroid toxicity seems to be a significant late complication of BMT in this setting, calling for close monitoring of all such children. Pasqualini et al 3 recommended TRH stimulation testing before stem cell transplantation, in order to detect subtle primary hypothyroidism. Screening for thyroid dysfunction was performed in 83.5% of our patients, and included palpation of nodules, and free T4 and TSH assay. Thyroid ultrasound was performed in only 23% of cases, and detected nodules in 28% of the patients concerned.
The incidence of UH was 9% in this study, in keeping with most earlier studies. [4] [5] [6] Nine of the 16 patients with UH had received TBI, and single-dose TBI carried a significantly higher risk of UH than fractionated TBI. 4, 6, 7 Likewise, Sanders et al 7 reported an incidence of UH of 15% after single-dose TBI and only 3% after fractionated TBI. In contrast, the latter authors found no significant difference between fractionated and hyperfractionated TBI. UH occurred in only one of the 13 patients who did not receive TBI in our study, confirming previous reports. 8 Thus, thyroid dysfunction can occur even after chemical conditioning regimens in childhood. Single-dose TBI does not appear to be superior to fractionated TBI, and the risk of thyroid dysfunction is a further argument against its use.
CH was considerably more common, affecting 31.4% of patients, in keeping with earlier data. 5, 8, 9, 10 Borgstro¨m and Thyroid toxicity in patients survivors of ABMT for ALL C Berger et al Bolme, 5 in particular, reported CH in 37% of patients. Again, the main risk factor was TBI, and especially singledose TBI. Other statistically significant risk factors were younger age at BMT (0-9 years vs X10 years) and BMT during CR2 (vs CR1).
The interval between BMT and diagnosis of thyroid dysfunction ranged between 1-10.3 years and 0.8-11 years in patients with UH and CH, respectively. Intervals reported in the literature range from 4 to 50 months. 8, 9 As thyroid dysfunction may develop several years after BMT and is often clinically silent, routine and regular thyroid function screening is mandatory. In our study, 13% of patients were taking THRT for UH (all the patients with UH) and 25% were taking THRT for CH (including 5% of patients with nodules). Furthermore, 3% of patients were taking THRT after surgical removal of thyroid nodules.
Thyroid cancer has not been diagnosed in any of our patients, but mean follow-up after BMT is only 9.3 years. In other reports, thyroid cancer was not detected in children transplanted for AML in first remission who were taking THRT for hypothyroidism after a mean follow-up of 6 years. 8, 11 In the study by Borgstro¨m and Bolme, 5 one of the 11 children with an exaggerated response to TRH did not receive THRT and was found to have multiple follicular thyroid adenomas at autopsy, 10 years after BMT. The cause of death was not specified. Cohen et al 12 reported that eight out of 113 patients developed thyroid cancer at a median of 10 years after BMT. Only one patient had a palpable nodule, but ultrasonography was performed annually. Three patients had an elevated TSH. In a retrospective study of 271 children, Sanders et al 7 found that 31% of patients treated with single-dose TBI had untreated CH. One of these patients subsequently had toxic goitre and another developed thyroid adenoma. Two patients had papillary carcinoma diagnosed 4 and 6 years after BMT, respectively. These authors recommended that prophylactic THRT be given routinely for 2-3 years, starting at the time of BMT, and that thyroid function should be evaluated 3-6 months after treatment discontinuation. We think that THRT should be started at the detection of CH or UH or thyroid nodules, with the aim of preventing nodule development and reducing the activity of existing nodules, thereby reducing the risk of papillary carcinoma. Furthermore, THRT has been shown to have benefits for growth and heart rate stability in this setting. 9 In conclusion, we recommend routine thyroid monitoring after BMT, including a physical examination every 6 months and freeT4 and TSH assay 6 months after BMT and annually thereafter. A TRH test should be carried out 2 years after BMT and repeated as indicated by TSH levels. Thyroid ultrasonography can be carried out 6 months after BMT and annually thereafter. We recommend THRT as soon as CH or UH is diagnosed, when a massively exaggerated response to TRH occurs, or when thyroid nodules are detected. 
